Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925 is registered in ClinicalTrials.gov with Dren Bio as lead sponsor.

NCT NCT05475925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05475925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Lead sponsor
Dren Bio
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 13, 2022
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive nk cell leukemia, cutaneous ptcl-nos (cd8+ or cd56+ and cytotoxic marker), cytotoxic ptcl-nos (cd8+ or cd56+ and cytotoxic marker), enteropathy-associated t-cell lymphoma, extranodal nk/t cell lymphoma, nasal type, hepatosplenic t-cell lymphoma, hydroa vacciniforme-like lymphoproliferative disorder, lgll - large granular lymphocytic leukemia, monomorphic epitheliotropic intestinal t-cell lymphoma, primary cutaneous cd8+ aggressive epidermotropic t-cell lymphoma, primary cutaneous gamma-delta t-cell lymphoma, subcutaneous panniculitis-like t-cell lymphoma, systemic ebv1 t-cell lymphoma, if cd8 positive